艾昆纬-印度药品市场季度洞察报告（英）-2023.5-6页_233kb

Indian Pharmaceutical Market Q1 2023 Insights

Overall Market Performance

• Market size in Q1 2023: ₹50,361 Crore, growing at 15% PPG.
• Previous quarter-to-quarter growth: 8% for the March 2022 quarter, 15% for Q1 2023.

Therapeutic Areas

Acute Therapeutics

• Overall growth: 15% PPG.
• Key drivers: Anti-infectives at 28% PPG, pain and gastrointestinal therapies.
• Respiratory acute and cough preparations showed strong growth.

Chronic Therapeutics

• Overall growth: 15% PPG.
• Top performers: Cardiac at 13% PPG (robust growth), Chronic Respiratory at 29% PPG, Neuro/CNS at 13% PPG.
• Anti-neoplastics, pain, uro, and hormones also grew at double-digit rates.

Company and Geographic Performance

Company Growth

• Indian pharmaceutical companies grew at 16% PPG, outperforming MNCs at 10% PPG.
• Top Indian performers: Sun Pharma, Cipla, Mankind, Alkem.
• Top MNC performers: Abbott, GSK, AstraZeneca.

Geographic Growth

• Leading zones: South (14% PPG) and North (16% PPG) with high contribution.
• Fastest growing regions: Uttar Pradesh, Maharashtra, West Bengal, Karnataka, Bihar, Telangana, Tamil Nadu.
• Market classes: Extra urban and metro areas grew at 15% and 14% PPG respectively.

Key Product Insights

• Anti-infectives: Cephalosporins declined (-30% PPG), but Ampicillin/amoxycillin and carbapenems grew strongly.
• Pain market driven by anti-rheumatic and nonsteroidal drugs at 14% PPG.
• Respiratory therapies: Cough preparations grew 33% PPG, with levosalbutamol leading.
• Diabetes treatments: Glimepiride+metformin grew 11% PPG, while insulin market showed single-digit growth.